TIMP3 and achalasia-alacrima syndrome: We present here novel in vivo findings that miR-181b inhibition reduces the progression of established atherosclerotic plaques and AAAs, mediated by increased expression of TIMP-3 in intraplaque and intra-aneurysm macrophages and elastin expression in VSMC.